The global Biliary Atresia Treatment Market is estimated to be valued at US$ 1,064.2 Mn in 2023 and is expected to exhibit a CAGR of 8.1% over the forecast period 2027 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Biliary atresia is a rare disease in infants that causes progressive destruction of the bile ducts within or outside the liver, resulting in cholestasis and progressive liver disease. The standard treatment for biliary atresia is the Kasai portoenterostomy surgery to reconnect the bile ducts. However, gene therapies aiming to cure the underlying cause are emerging as a promising alternative treatment approach.
Market key trends:
One of the major trends gaining traction in the market is increasing research and development of gene therapies for the treatment of biliary atresia. Gene therapies offer the potential to cure the disease by correcting the genetic abnormalities underlying biliary atresia. Some of the gene therapies under investigation target genetically modifiable mechanisms like cystic fibrosis transmembrane conductance regulator (CFTR) function. Positive results from ongoing clinical trials evaluating the safety and efficacy of gene therapies could significantly boost their adoption over the forecast period.
Segment Analysis
The global biliary atresia treatment market is segmented based on treatment type, end user, and region. Based on treatment type, the market is segmented into medication, surgery, and liver transplant. The surgery segment dominates the market as it is the most effective and permanent treatment option for biliary atresia. Kasai portoenterostomy is the most commonly performed surgical procedure to restore bile duct flow in children diagnosed with biliary atresia.
Key Takeaways
Market size: The global biliary atresia treatment market is expected to witness high growth, exhibiting CAGR of 8.1% over the forecast period, due to increasing prevalence of biliary atresia, rising healthcare expenditure, and growing awareness regarding treatment options.
Regional analysis: North America dominates the global market owing to high healthcare spending and availability of advanced treatment options in the region. The Asia Pacific region is expected to grow at the fastest rate during the forecast period due to increasing cases of biliary atresia, rising healthcare expenditure, and improving healthcare infrastructure in emerging economies.
Key players: Key players operating in the biliary atresia treatment market are AstraZeneca plc, Eisai Co., Ltd., Mirum Pharmaceuticals, Inc., Pfizer Inc., Albireo Pharma, Inc., Novartis AG, Alkem Labs, and Glenmark Pharmaceuticals. Eisai Co., Ltd. and Pfizer Inc. dominate the market due to their extensive portfolio of treatment options and global commercial presence.
No comments:
Post a Comment